Cudratricusxanthone A has potent anti-proliferative, antioxidative, and Monoamine Oxidase inhibitory effects, it also possesses anti-cancer activities and provide a basis for developing effective tHERapeutic agents to inhibit growth and metastasis of breast cancer. Cudratricusxanthone A inhibits lipopolysaccharide-induced neuroinflammation through inhibition of NF-Κb and p38 MAPK pathways in BV2 microglia. Cudratricusxanthone A has antiplatelet, anticoagulant, and profibrinolytic activities, it reversibly inhibits CYP1A2, 2C8, and 2C9. It also exhibits the significant hepatoprotective effect on nitrofurantoin-induced cytotoxicity in human liver-derived Hep G2 cells.

Cudratricusxanthone A has potent anti-proliferative, antioxidative, and monoamine oxidase inhibitory effects, it also possesses anti-cancer activities and provide a basis for developing effective therapeutic agents to inhibit growth and metastasis of breast cancer. Cudratricusxanthone A inhibits lipopolysaccharide-induced neuroinflammation through inhibition of NF-κB and p38 MAPK pathways in BV2 microglia. Cudratricusxanthone A has antiplatelet, anticoagulant, and profibrinolytic activities, it reversibly inhibits CYP1A2, 2C8, and 2C9. It also exhibits the significant hepatoprotective effect on nitrofurantoin-induced cytotoxicity in human liver-derived Hep G2 cells.

740810-42-8

C23H24O6

396.43

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years